CALR Mutation–Directed Agents and Targeted Therapies Represent Key Research Avenue in MPN Management
Key claim: CALR mutation–directed agents and precision medicine approaches targeting JAK2, CALR, and MPL driver mutations represent a key emerging research avenue in MPN management, alongside new trial data for selinexor, pelabresib, and imetelstat.
Abstract
Expert commentary from Dr. Aaron Gerds on recent clinical trial data including the phase 3 SENTRY trial (selinexor plus rituximab) that met its first co-primary endpoint in March 2026, showing statistically significant spleen volume reduction in myelofibrosis. Discussion of pelabresib (BET inhibition) in MANIFEST-3, imetelstat data from IMpactMF, and precision medicine approaches targeting individual driver mutations (JAK2, CALR, MPL).
Why this matters
This expert review situates individual investigational MPN agents within a coherent precision-medicine narrative: CALR mutation–directed therapies (e.g., JNJ-88549968) and driver-mutation targeting are emerging as the next frontier beyond JAK inhibition, while near-term practice change is being driven by SENTRY (selinexor+ruxolitinib), MANIFEST-2 (pelabresib), and imetelstat readouts. For the treatments vault, it provides a synthesizing scaffold that links otherwise siloed pipeline pages — BET inhibitors, XPO1 inhibitors, and novel CALR-directed agents — into a shared strategic context.